Background. Combination therapy with cytotoxic drugs and corticosteroids reduces the risk for renal failure in patients with proliferative lupus nephritis (PLN ), but uncertainty remains about the best mode of immunosuppression and its long-term effects. We report long-term results of combined azathioprine-prednisolone treatment for PLN, which has been the therapy of choice for the treatment of PLN at our centre for 15 yr.
Therapy for proliferative lupus nephritis (PLN ) is still any specific immunosuppressant is established' [16 ] . With equal efficacy of the various agents, toxicity controversial, despite nearly 50 yr of clinical experience and research. Whereas treatment with low-dose corticobecomes an important consideration, and i.v. cyclophosphamide carries a significantly higher risk for serious steroids was soon found to be ineffective, high-dose corticosteroids (introduced only after an accidental morbidity than azathioprine [4, [17] [18] [19] . Concerns about the efficacy:toxicity ratio combined with practical probobservation on overdosing) slowed the progression of renal lesions and increased the 5-yr survival rate to 31% lems in administering i.v. cyclophosphamide to patients living several hundred kilometres away from this [1, 2] . The subsequent addition of immunosuppressive agents to corticosteroid therapy has led to further hospital are the reason that azathioprine has been the standard treatment for PLN patients in this hospital for improvements in prognosis, although PLN still carries a 10-25% risk of end-stage renal failure ( ESRF ) [3, 4] .
15 yr, and this report describes the results of that policy. As a result of several reports from the National Institutes of Health (NIH ) group, intermittent intravenous Patients and methods ('pulse') administration of cyclophosphamide has Patients become the standard of therapy in PLN [5] [6] [7] , although it is not equally successful in all hands in reducing the This department of rheumatology became fully operarisk of ERSF [8] [9] [10] . Several studies found azathioprine tional in 1978 and serves a population of 225 000 in the to be an effective adjuvant to corticosteroids in the two most northern counties of Norway. All patients treatment of PLN [4, [11] [12] [13] [14] [15] as the standard therapy, were not included (n = 8). and male patients tended to be older (mean age 51.3 yr were made to 50 mg daily followed by 25 mg dose vs. 26.5 for females, P = 0.09). Fourteen patients (54%) increases at longer intervals. The median duration of presented with LN at systemic lupus erythematosus azathioprine treatment was 53 months (range 2-184).
(SLE ) diagnosis, and 12 developed LN after a median In 20 (77%), the first occurrence of PLN was docudisease duration of 84 months (range 11-276). Nineteen mented by renal biopsy ( WHO class III, n = 5, WHO per cent of patients had renal insufficiency with serum class IV, n = 15). Six patients did not have histological creatinine levels >150 mmol/l at diagnosis; nephrotic confirmation of PLN. Three had rapidly progressive range proteinuria (>3.5 g per day) was present in 10 glomerulonephritis (and received methylprednisolone patients (39%), and high disease activity (SLEDAI score 1000 mg i.v. on 3 consecutive days as initial treatment), >10) in 18 patients (62%). The median follow-up time one patient refused biopsy, one had thrombocytopenia to the last visit or death was 119 months (range 5-277). <50 000 (with WHO class III lesions on renal biopsy Four patients discontinued azathioprine because of perduring a later renal relapse) and one had a severe sistent clinical (n = 2) or laboratory-detected side-effects psychosis, precluding biopsy. All six patients had a (n = 2) despite dose reductions. The median dose of nephrotic-nephritic presentation with positive tests for azathioprine was 125 mg (range 75-200) and the median anti-double-stranded DNA (anti-dsDNA) antibodies prednisolone dose 7.5 mg (range 0-40) 12 months after and/or hypocomplementaemia, indicative of PLN [4] . PLN diagnosis. Nineteen renal flares occurred in 12 Two patients with biopsy-proven PLN were treated patients, with a mean interval of 414 days between LN otherwise: one received oral cyclophosphamide initially diagnosis and first flare; 16 flares (85%) were accompanand was switched to azathioprine first after 6 months, ied by positive anti-dsDNA and/or low serum compleand one patient received prednisolone monotherapy as ment factors. Figure 1 shows the cumulative frequencies she refused any cytotoxic medication. Both patients of various disease manifestations in this cohort. were excluded from this analysis, which thus included 26 patients. Disease activity was measured by SLEDAI Survival analysis (systemic lupus erythematosus disease activity index) Seven patients (27%) died, after a mean disease duration [21] , and damage development was assessed by the of 180 months. Patient survival rate at 5, 10 and 15 yr Systemic Lupus International Collaborating Clinics was 96, 91 and 82%, respectively ( Fig. 2A) . In a univari-(SLICC )-ACR damage index [22] . Hypertension was ate survival analysis we found that age <30 yr considered present if blood pressure exceeded 150/90 in (P < 0.04), male sex (P < 0.001), persistence of protwo separate measurements and was considered susteinuria for >6 months (P = 0.02) and the presence at tained if present for >6 months. Hypertension was any time of discoid lesions (P < 0.03) were associated managed in a step-up fashion using vasodilators, diurwith poorer survival, but only the last two variables etics and beta-blocking agents. Renal flares were defined remained independent predictors in a multivariate as a >50% increase in proteinuria with an active urinary sediment and were managed initially by increasing the prednisolone dose to 0.5-1 mg/kg. Anti-dsDNA testing T performed by the use of Kaplan-Meier estimates and
No. with diastolic blood pressure Á100 mmHg (%) 3 (11) differences in survival curves analysed by log-rank test-F. 1. Cumulative frequency of non-renal SLE manifestations in patients with PLN (n = 26).
analysis (P = 0.04 and 0.02, respectively). Four patients patients progressing to ESRF, two patients developed renal insufficiency, their latest recorded serum creatinine (15%) developed end-stage renal failure and required chronic haemodialysis. One patient died after 6 months levels being 278 and 165 mmol. The number of patients with diastolic hypertension had increased to 10 (38%), on dialysis, and three received successful renal transplants after a mean time of 27 months on dialysis. Renal and serological evidence of disease activity (presence of anti-dsDNA and/or low C3/C4 levels) was still detected survival rates at 5, 10 and 15 yr ( Fig. 2B) were 92, 87 and 87%, respectively. Poor renal survival was independin almost 20% of patients. Sixteen patients were still using azathioprine and all patients were still using ently associated with the presence of sustained arterial hypertension (P = 0.005), but not with renal flares prednisolone (median dose 7.5 mg, range 5-40). No malignancies were diagnosed during the time of (P = 0.09) or any of the lupus manifestations included in Fig. 1 (all P values >0.1 ). We performed a separate observation. life-table analysis to determine the risk of any bad outcome (end-points of death or ESRF ), which showed Discussion an 11.5% risk for either death or ESRF 2 yr after LN diagnosis, that increased to nearly 30% after 10 yr and When the mercaptopurine derivative azathioprine was to 47% after 15 yr (Fig. 2C ). Patient and renal survival found to reduce antibody production, prolong graft estimates for the six patients without histological evisurvival in renal transplant patients and reduce the dence of PLN did not differ from survival estimates in severity of experimental lupus nephritis, it soon found the 20 patients with biopsy-proven PLN (P > 0. 2 Table 2 summarizes the clinical findings in the surviving that azathioprine has a place in the treatment of PLN patients at the last follow-up. In addition to the four [15, 16, 27] . The 10-yr patient survival rate of 91% in our cohort not only represents a large improvement over rates reported 40 yr ago using high-dose steroid survival analysis as patient survival no longer requires
No. with SLICC-ACR score Á 1 (%) 11 (48) ESR (mm/h) (range) 34 renal survival if access to dialysis is available. ESRF,
No. with anti-dsDNA antibodies 2 (9) although still unwelcome, is now a treatable condition
No. with systolic blood pressure Á160 mmHg (%) 4 (17) and lupus patients do at least as well as other patient
No. with diastolic blood pressure Á100 mmHg (%) 6 (26) groups in renal replacement programmes [29, 30] . One prolonged proteinuria and hypertension with poorer prognosis indicates a substantial role for such supportive therapies in improving the prognosis [31, 32] . Four of our patients developed ESRF (15%), which is well within the range of rates reported in the literature, although it is nearly double the 8% rate reported in the latest NIH study [7, 8, 15] . In that study, however, follow-up was relatively short; renal failure in PLN usually results from a slow decline in renal function, which may be independent of the initial insult, while renal lupus flares may accelerate this decline [33, 34] . In contrast to crude ESRF rates, survival analysis allows evaluation of the time-dependence of this complication of PLN, and a minimum observation time of 100 months for therapeutic studies on PLN has been proposed [35] . This study's single-centre design allowed consistent longterm follow-up. The renal survival at 5 yr was 92% in this cohort, which compares favourably with the 75-88% reported in a recent review [25] ; the 10-and 15-yr renal survival rates of 87% are similar to that reported for i.v. cyclophosphamide in the longer-term NIH study [35] . Angiotensin converting enzyme-inhibiting agents are now known to have renoprotective effects in various forms of glomerulonephritis [33] , but as only three (hypertensive) patients were treated with ACE inhibitors in this study no conclusion can be drawn.
Our study patients were not remarkable in terms of age, gender, renal function, other lupus manifestations or autoimmune serology, but the regional aspect of this study is nonetheless of importance. All our patients were Caucasians of Nordic descent, whereas most US-based studies include a considerable number of patients of African heritage, who tend to have a worse disease outcome because of both intrinsic medical and socioeconomic factors [28] . This considerably limits one's ability to extrapolate the NIH data on the benefit of cyclophosphamide therapy for PLN [36 ] and calls for homogeneous study populations. More than half of our patients were treated at the very beginning of their disease, which may be an additional reason for the good results of azathioprine therapy in our cohort. The timing of immunosuppression has been considered an important prognostic factor in LN, and providing early immunosuppression may be even more important than the type of immunosuppression given [37, 38] .
Our results indicate that 15 yr after diagnosis, and despite the relative efficacy of azathioprine, patients had a risk of nearly 50% of an adverse outcome in the form of a control group, its retrospective nature and the relatively small number of cases. This notwithstanding, we feel that the homogeneity of our cohort, the consistcan speculate whether the use of azathioprine is the sole explanation of this improved survival. Many novel ency in patient management and the long-term followup make these findings worthwhile. treatments have become available for non-lupus-specific complications such as hypertension, hyperlipaemia,
In conclusion, treatment of PLN with prednisolone and azathioprine was well tolerated and associated with hypercoagulation and proteinuria. The association of
